ge_healthcare_kieran_murphy

Kieran Murphy to head up life sciences for GE Healthcare

pharmafile | February 23, 2011 | Appointment | Research and Development, Sales and Marketing GE Healthcare, Kieran Murphy, appointment, research and development, sales and marketing 

GE Healthcare has promoted Kieran Murphy to succeed its current Life Sciences president and chief executive Peter Ehrenheim.

Kieran, who is currently head of GE Healthcare’s Life Sciences global commercial operations, will take up his new post on 1 April and Peter who will retire from GE after a transition period on 31 July.

GE Healthcare president and chief executive John Dineen said: “Peter is handing over the Life Sciences business to Kieran in great shape, with record 2010 results, a strong portfolio and ambitious growth plans. We thank Peter for his leadership, his 28-year contribution to the business, and we look forward to a smooth transition into Kieran’s hands.

Advertisement

“Our Life Sciences business is a key part of GE Healthcare and its strategy. Peter has been instrumental in growing and reshaping it since taking charge in 2006. Kieran’s energy, imagination and commercial focus make him ideally suited to continue driving the business forward,” he added.

Kieran joined GE upon its acquisition of Whatman, where he was chief executive, in 2008.

His pharma career, which spans more than 20 years, began at Janssen and encompassed roles at Mallinckrodt, veterinary medicines business Vericore, Adprotech, Innovata and Novartis.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content